Close
Top Videos
Top Searches
Moods
Black Lives Matter
Chill
Christmas
Commute
Energy boosters
Feel-Good
Focus
Party
Pride
Romance
Sad
Sleep
Workout
Genres
African
Arabic
Blues
Bollywood & Indian
Christian & Gospel
Classical
Country and Americana
Dance and electronic
Decades
Family
Folk and acoustic
Hip-hop
Indie and alternative
J-Pop
Jazz
K-Pop
Latin
Mandopop & Cantopop
Metal
Pop
R&B and Soul
Reggae and Caribbean
Rock
Soundtracks and musicals
European Society of Cardiology: 2022 cardio-oncology guidelines
01:26
|
Download MP3
Related Videos
5:11
iStopMM: the psychological effects of MGUS screening and changes to clinical presentation of myeloma
1:16
The efficacy of CAR T-cell therapy in Richter’s transformation
1:31
Frontline treatment for CLL: the changing paradigm
3:08
Welcome to the Video Journal of Hematology & Hematological Oncology 🎥🩸
1:41
Triplet vs quadruplet regimens for NDMM: selecting between these options
0:44
Early detection and interception across hematological cancers
4:40
Whole genome sequencing of cfDNA as a non-invasive method for MRD detection in multiple myeloma
2:01
The evolution of BCL2 inhibition in CLL
1:04
A trial by WM-NET investigating bendamustine, rituximab, and fixed-duration zanubrutinib in WM
1:01
Exploring the biological mechanisms driving MBL progression to CLL
1:11
Gene therapy for SCD: unanswered questions
2:13
Personalizing the timing of SCT in patients with myelofibrosis
2:26
An insight into the aims of the Eurasian Hematology-Oncology Group
1:15
The diagnosis and management of MDS/MPN with neutrophilia (atypical CML)
4:55
Immune profiling of BM microenvironment to identify predictors of disease progression in myeloma
3:02
The role of asparaginase in the treatment of ALL
1:22
Managing adverse events associated with BTKis when treating patients with MCL
1:13
The main treatment goals in LR-MDS and how these differ from HR-MDS
2:10
A study investigating the incidence of treatment-emergent autoimmune cytopenias in CLL
2:55
A model including CD49d expression to predict outcomes in patients with CLL treated with ibrutinib
5:11 1:16 1:31 3:08 1:41 0:44 4:40 2:01 1:04 1:01 1:11 2:13 2:26 1:15 4:55 3:02 1:22 1:13 2:10 2:55
